iwNHL 2015 | Emerging monoclonal antibodies for lymphoma therapy

Thomas Kipps

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Thomas J. Kipps, MD, PhD, of the University of California, San Diego, San Diego, CA, discusses novel monoclonal antibodies against CD20, including rituximab, ofatumumab and obinutuzumab, that are progressing in clinical development as single agents and in combination for the treatment of patients with non-Hodgkin lymphoma.

Share this video